145 related articles for article (PubMed ID: 33420642)
1. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers.
Wu M; Li X; Sun J; Chen H; Ding Y
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):503-508. PubMed ID: 33535835
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
[TBL] [Abstract][Full Text] [Related]
4. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults.
Pierce D; Corcoran M; Velinova M; Hossack S; Hoppenbrouwers M; Martin P
Drug Des Devel Ther; 2015; 9():1257-68. PubMed ID: 25767373
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J; Gießmann T; Lang B; Elgadi M; Huang F
J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
9. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
10. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
12. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA; Breitschaft A; Navarria A; Hansen CW
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):869-877. PubMed ID: 29897249
[TBL] [Abstract][Full Text] [Related]
13. Clinical study of drug-drug interaction between omeprazole and pyrotinib after meal.
Li X; Wang Y; Zhu X; Zheng L
Br J Clin Pharmacol; 2022 May; 88(5):2349-2358. PubMed ID: 34873745
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Hwang KG; Kim YS; Shaw LM; Lee YS; Kang JS
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):23-9. PubMed ID: 19203529
[TBL] [Abstract][Full Text] [Related]
16. Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
Patel G; Gupta VK; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149522. PubMed ID: 36943038
[TBL] [Abstract][Full Text] [Related]
17. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects.
Sun F; Liu Y; Li T; Lin P; Jiang X; Li X; Wang C; Gao X; Ma Y; Fu Y; Cao Y
BMC Pharmacol Toxicol; 2023 Feb; 24(1):7. PubMed ID: 36737825
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Chong E; Kalia V; Willsie S; Winkle P
J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
